Document Detail


G2 checkpoint abrogators as anticancer drugs.
MedLine Citation:
PMID:  15078995     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Many conventional anticancer treatments kill cells irrespective of whether they are normal or cancerous, so patients suffer from adverse side effects due to the loss of healthy cells. Anticancer insights derived from cell cycle research has given birth to the idea of cell cycle G2 checkpoint abrogation as a cancer cell specific therapy, based on the discovery that many cancer cells have a defective G1 checkpoint resulting in a dependence on the G2 checkpoint during cell replication. Damaged DNA in humans is detected by sensor proteins (such as hHUS1, hRAD1, hRAD9, hRAD17, and hRAD26) that transmit a signal via ATR to CHK1, or by another sensor complex (that may include gammaH2AX, 53BP1, BRCA1, NBS1, hMRE11, and hRAD50), the signal of which is relayed by ATM to CHK2. Most of the damage signals originated by the sensor complexes for the G2 checkpoint are conducted to CDC25C, the activity of which is modulated by 14-3-3. There are also less extensively explored pathways involving p53, p38, PCNA, HDAC, PP2A, PLK1, WEE1, CDC25B, and CDC25A. This review will examine the available inhibitors of CHK1 (Staurosporin, UCN-01, Go6976, SB-218078, ICP-1, and CEP-3891), both CHK1 and CHK2 (TAT-S216A and debromohymenialdisine), CHK2 (CEP-6367), WEE1 (PD0166285), and PP2A (okadaic acid and fostriecin), as well as the unknown checkpoint inhibitors 13-hydroxy-15-ozoapathin and the isogranulatimides. Among these targets, CHK1 seems to be the most suitable target for therapeutic G2 abrogation to date, although an unexplored target such as 14-3-3 or the strategy of targeting multiple proteins at once may be of interest in the future.
Authors:
Takumi Kawabe
Related Documents :
10738085 - Variation in sensitizing effect of caffeine in human tumour cell lines after gamma-irra...
6801505 - Differential sensitivity of muntjac lymphocyte chromosomes to mitomycin c, bromodeoxyur...
9245695 - Staurosporine induces telophase arrest and apoptosis blocking mitosis exit in human cha...
6825155 - A cell kinetic method for the mitotic selection of treated g2 cells.
19874815 - Pulsation and stabilization: contractile forces that underlie morphogenesis.
11991965 - Infection of cells with human cytomegalovirus during s phase results in a blockade to i...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Molecular cancer therapeutics     Volume:  3     ISSN:  1535-7163     ISO Abbreviation:  Mol. Cancer Ther.     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-04-13     Completed Date:  2004-11-23     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  101132535     Medline TA:  Mol Cancer Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  513-9     Citation Subset:  IM    
Affiliation:
CanBas Co. Ltd., Numazu, Japan. takumi@canbas.co.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / pharmacology*
Cell Cycle Proteins / antagonists & inhibitors,  metabolism
G1 Phase / physiology
G2 Phase / drug effects*,  physiology
Humans
Neoplasms / drug therapy*,  pathology*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Cell Cycle Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer p...
Next Document:  Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of...